BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31402273)

  • 1. CD8+CD103+ iTregs Inhibit Chronic Graft-versus-Host Disease with Lupus Nephritis by the Increased Expression of CD39.
    Zhang X; Ouyang X; Xu Z; Chen J; Huang Q; Liu Y; Xu T; Wang J; Olsen N; Xu A; Zheng SG
    Mol Ther; 2019 Nov; 27(11):1963-1973. PubMed ID: 31402273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TGF-β-Induced CD8
    Zhong H; Liu Y; Xu Z; Liang P; Yang H; Zhang X; Zhao J; Chen J; Fu S; Tang Y; Lv J; Wang J; Olsen N; Xu A; Zheng SG
    Front Immunol; 2018; 9():35. PubMed ID: 29441062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD8+CD103+ iTregs inhibit the progression of lupus nephritis by attenuating glomerular endothelial cell injury.
    Deng W; Xu M; Meng Q; Li Z; Qiu X; Yin S; Sun D; Dai C; Liu Y
    Rheumatology (Oxford); 2019 Nov; 58(11):2039-2050. PubMed ID: 31329981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD8+iTregs attenuate glomerular endothelial cell injury in lupus-prone mice through blocking the activation of p38 MAPK and NF-κB.
    Liu Y; Deng W; Meng Q; Qiu X; Sun D; Dai C
    Mol Immunol; 2018 Nov; 103():133-143. PubMed ID: 30268079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic and functional characteristic of a newly identified CD8+ Foxp3- CD103+ regulatory T cells.
    Liu Y; Lan Q; Lu L; Chen M; Xia Z; Ma J; Wang J; Fan H; Shen Y; Ryffel B; Brand D; Quismorio F; Liu Z; Horwitz DA; Xu A; Zheng SG
    J Mol Cell Biol; 2014 Feb; 6(1):81-92. PubMed ID: 23861553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transforming growth factor-beta1-induced CD4+CD25+ regulatory T cells in vitro reverse and prevent a murine lupus-like syndrome of chronic graft-versus-host disease.
    Su H; Ye DQ; Wang BL; Fang XH; Chen J; Wang Q; Li WX; Zhang N
    Br J Dermatol; 2008 Jun; 158(6):1197-209. PubMed ID: 18410422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD8(+)CD103(+) regulatory T cells in spontaneous tolerance of liver allografts.
    Lu L; Yu Y; Li G; Pu L; Zhang F; Zheng S; Wang X
    Int Immunopharmacol; 2009 May; 9(5):546-8. PubMed ID: 19539566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associated with immunological remission of lupus.
    Zhang L; Bertucci AM; Ramsey-Goldman R; Burt RK; Datta SK
    J Immunol; 2009 Nov; 183(10):6346-58. PubMed ID: 19841178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin C stabilizes CD8+ iTregs and enhances their therapeutic potential in controlling murine GVHD and leukemia relapse.
    Iamsawat S; Tian L; Daenthanasanmak A; Wu Y; Nguyen HD; Bastian D; Yu XZ
    Blood Adv; 2019 Dec; 3(24):4187-4201. PubMed ID: 31856270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-aminolevulinic acid combined with sodium ferrous citrate ameliorated lupus nephritis in a mouse chronic graft-versus-host disease model.
    Liu C; Wang Z; Hu X; Ito H; Takahashi K; Nakajima M; Tanaka T; Zhu P; Li XK
    Int Immunopharmacol; 2021 Jul; 96():107626. PubMed ID: 33862551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell specific defect in expression of the NTPDase CD39 as a biomarker for lupus.
    Loza MJ; Anderson AS; O'Rourke KS; Wood J; Khan IU
    Cell Immunol; 2011; 271(1):110-7. PubMed ID: 21763644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo.
    Zhang P; Tey SK; Koyama M; Kuns RD; Olver SD; Lineburg KE; Lor M; Teal BE; Raffelt NC; Raju J; Leveque L; Markey KA; Varelias A; Clouston AD; Lane SW; MacDonald KP; Hill GR
    J Immunol; 2013 Nov; 191(10):5291-303. PubMed ID: 24123683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ex vivo induction of human CD103⁺ CD25hi Foxp3⁺ CD4⁺ and CD8⁺ Tregs is IL-2 and TGF-β1 dependent.
    Gunnlaugsdottir B; Maggadottir SM; Skaftadottir I; Ludviksson BR
    Scand J Immunol; 2013 Feb; 77(2):125-34. PubMed ID: 23126599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of CD103 expression by CD8+ T cells responding to renal allografts.
    Wang D; Yuan R; Feng Y; El-Asady R; Farber DL; Gress RE; Lucas PJ; Hadley GA
    J Immunol; 2004 Jan; 172(1):214-21. PubMed ID: 14688328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGF-{beta}-dependent CD103 expression by CD8(+) T cells promotes selective destruction of the host intestinal epithelium during graft-versus-host disease.
    El-Asady R; Yuan R; Liu K; Wang D; Gress RE; Lucas PJ; Drachenberg CB; Hadley GA
    J Exp Med; 2005 May; 201(10):1647-57. PubMed ID: 15897278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD103 is a marker for alloantigen-induced regulatory CD8+ T cells.
    Uss E; Rowshani AT; Hooibrink B; Lardy NM; van Lier RA; ten Berge IJ
    J Immunol; 2006 Sep; 177(5):2775-83. PubMed ID: 16920912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human gingiva-derived mesenchymal stem cells are therapeutic in lupus nephritis through targeting of CD39
    Dang J; Xu Z; Xu A; Liu Y; Fu Q; Wang J; Huang F; Zheng Y; Qi G; Sun B; Bellanti JA; Kandalam U; Emam HA; Jarjour W; Zheng SG
    J Autoimmun; 2020 Sep; 113():102491. PubMed ID: 32565049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-12 and IL-4 activate a CD39-dependent intrinsic peripheral tolerance mechanism in CD8(+) T cells.
    Noble A; Mehta H; Lovell A; Papaioannou E; Fairbanks L
    Eur J Immunol; 2016 Jun; 46(6):1438-48. PubMed ID: 26990545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors.
    Duhen T; Duhen R; Montler R; Moses J; Moudgil T; de Miranda NF; Goodall CP; Blair TC; Fox BA; McDermott JE; Chang SC; Grunkemeier G; Leidner R; Bell RB; Weinberg AD
    Nat Commun; 2018 Jul; 9(1):2724. PubMed ID: 30006565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4+CD25+Foxp3+ regulatory T cells are dispensable for controlling CD8+ T cell-mediated lung inflammation.
    Tosiek MJ; Gruber AD; Bader SR; Mauel S; Hoymann HG; Prettin S; Tschernig T; Buer J; Gereke M; Bruder D
    J Immunol; 2011 Jun; 186(11):6106-18. PubMed ID: 21518973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.